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Lung transplantation is currently the most effective means of improving survival and quality of life in patients with end-stage cystic
fibrosis. In reviewing our 6-year experience we sought to evaluate complications and survival after sequential bilateral lung
transplantation.
Between October 1996 and October 2002, 114 patients with cystic fibrosis were referred to us from 15 Italian regional centers and 2
support centers for cystic fibrosis as possible candidates for lung transplantation. Of these 114 patients, 99 were included in the waiting list
and 15 were refused. The mean time spent on the waiting list was 6.8T5.2 months (range 1 day–21 months) for those patients receiving lung
transplantation, and 5.4T4.5 months (range 10 days–18 months) for those 35 patients who died while on the waiting list. A total 55 patients
(6 children and 49 adults), mean age 25.6T6.6 years (range 9–52 years), 29 males, underwent bilateral sequential lung transplantation. One
patient had a second transplantation 14 months after the first.
The most frequent medical non-infective complications after transplantation were chronic renal failure (n =27 patients), diabetes
(n =31), osteoporosis (n =17), arterial hypertension (n =14), seizures (n =4), transient cerebral ischaemia (n =1), and transient bilateral
blindness (n =1). Bacterial lower airways respiratory infections with the organisms that colonized patients’ airways before lung
transplantation developed in 42 patients; cytomegalovirus (CMV) infection in 41; and opportunistic infections of the lung with
Pneumocystis carinii in 3 patients. Cultures of sputum or bronchoalveolar lavage fluid grew Aspergillus fumigatus in nine patients;
aspergillosis of right bronchial anastomosis developed in one patient and a lung infection in another. Another patient had a pulmonary
infection secondary to Aspergillus niger.
An average of 1.3 episodes of acute rejection developed per patient in the first 6 months after lung transplantation. Freedom from
bronchiolitis obliterans syndrome was 95% at 1 year, 82.5% at 2 years, 70% at 3 years, and 65% at 4, 5 and 6 years. Actuarial survival rates
were 80% at 1 month, 79% at 1 year, 74% at 2 years, 70% at 3 years and 58% at 4, 5 and 6 years. Ten patients (17.8%) died in the early
postoperative period (1–30 days) for the following reasons: primary graft failure (n =4), multiorgan failure (n =3), Burkholderia cepacia
sepsis (n =1), myocardial infarction (n =1), and pulmonary embolism (n =1). Mortality was accounted for by 9 patients (16%) who died from
9 to 43 months after lung transplantation, for the following reasons: P. carinii infection (n =2), bronchiolitis obliterans syndrome (n =4),
A. fumigatus pulmonary infection (n =1), unknown cause (n =1) and suicide (n =1).
In conclusion, the leading causes of morbidity after lung transplantation for cystic fibrosis are pulmonary bacterial infection and
opportunistic infections. Bronchiolitis obliterans develops in more than half of lung transplant recipients who survive for more than 3 years
and is an important cause of death in the late post transplantation period.
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Cystic fibrosis (CF), the most common inherited
disease, affects approximately one every 3400 live births4 (2005) 107 – 114uropean Cystic Fibrosis Society.
Table 1
Clinical features of transplant recipients
Age (years) 25.6T6.6 years
Gender male 29
BMI (body mass index) 17.3T2.1 kg/m2
PaP 21.0T4 mm Hg
FEV1 (% of the predictive value) 25.4T6%
FVC (% of the predictive value) 38.0T8%
Mean time on the waiting list 6.8T5.2 months
Mean length of hospitalization after transplantation 33T8.2 days
S. Quattrucci et al. / Journal of Cystic Fibrosis 4 (2005) 107–114108[1]. In Italy the incidence is estimated one every 4700 live
births and varies widely among regions [2]. Thanks to
recent therapeutic advances, most patients now survive to
adult age [3,4]. CF is a systemic disease and more than 95%
of patients die from respiratory failure [5].
In recent years lung transplantation has emerged as the
most effective means for improving survival and quality
of life in patients with CF who have end-stage lung
disease. Among factors that have helped to lower
mortality rates and improve the outcome after trans-
plantation are improved selection criteria, graft preserva-
tion and perioperative management, along with more
effective immunosuppressive therapy and prophylaxis of
opportunistic infection [6–10]. The success of lung
transplantation and patients’ long-term survival also
depend crucially on the timing for referral of patients
with CF for transplantation, the onset of pulmonary
infections, and the development of chronic pulmonary
rejection [8,11].
Owing to the complexity of the disease and management
problems before and after transplantation, patients with CF
pose a challenge for any lung transplantation program. Even
so, survival rates have now reached 91% at 1 year, 83% at 3
years and 76% at 5 years [12].
In 1993 the Italian government enacted a law that
established regional and support centres (in the most
densely populated region) for the diagnosis, treatment and
research into CF [13]. As a result, 20 regional and 7
support centres were identified. Each of these receives
special national funds every year, and offer Italian
patients with CF all medical care free of charge. In
1996 a national program for bilateral sequential lung
transplantation in patients with CF started in Italy and the
regional centre in Rome was one of the original pilot
centres.
This study was designed to review our 6-year
experience of bilateral sequential lung transplantation for
patients with CF. Our primary aim was to evaluate
complications developing during follow-up, the incidence
of acute rejection, the rate of development of bronchiolitis
obliterans syndrome and long-term survival.2. Material and methods
2.1. Patients
Between October 1996 and October 2002, 114 consec-
utive patients, referred from 15 Italian regional and 2
support centres to the regional centre in Rome, Policlinico
Umberto I, University ‘‘La Sapienza’’, were evaluated as
candidates for lung transplantation. Of these 114 patients,
55 (6 children and 49 adults) (mean age 25.6T6.6 years,
range 9–52 years), the subject of this review, underwent
bilateral sequential lung transplantation. Table 1 lists their
clinical features.2.2. Patients selection
Patients scheduled for lung transplantation all had to
fulfill the following criteria: 24-h oxygen requirement;
continuous need of systemic antibiotics defined as one
intravenous (IV) antibiotic treatment at least every month;
rapid decrement in forced expiratory volume in 1 s (FEV1)
under 30% of the predicted value; progressive and
uncorrectable weight loss; and unacceptably poor quality
of life. As the absolute and relative contraindications for
lung transplantation our centre used those reported by
Trulock in 1997 [14]. Patients considered candidates for
transplantation underwent thorough functional assessment
of the lung and a general clinical assessment. Specific
pulmonary evaluation consisted of lung-function tests, room
air blood gas, 6-min walk test, perfusion lung scan and high
resolution computed tomographic scan. Cardiac evaluation
consisted of echocardiogram and right cardiac catheter-
ization. Other studies included functional assessment of the
kidney, liver and the endogenous pancreas. The patient’s
microbiological profile was obtained by sputum culture or
bronchoalveolar lavage together with serological test for
CMV, Epstein Barr virus (EBV), herpes virus (HV), human
immunodeficiency virus (HIV), hepatitis A, B, C, and
toxoplasma. Patients and their families then underwent
psychosocial assessment. Because patients with CF receive
all medical care free of charge in Italy their financial
resources were not investigated.
Once scheduled for transplantation patients started a
monthly follow-up and received a regimen of appropriate
antibiotics, aggressive feeding, exercise and chest physi-
otherapy, with the aim of maximizing pulmonary function
and overall physical condition before transplantation.
Patients referred from elsewhere were followed in the
referring centre, whereas the others were followed in Rome.
Monthly clinical information about patients on the waiting
list was communicated to the regional centre in Rome from
the referring centre.
Organs were selected from size-matched donors in
identical ABO blood groups. Owing to young age of
patients with CF only nonmarginal organs were used.
2.3. Transplant procedure
All patients had bilateral sequential lung transplantation
as previously described [15,16] at the Department of
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Rome ‘‘La Sapienza’’. For the first 29 patients treated we
used a bilateral thoracosternotomy (‘‘clamshell’’) incision
and for the last 26 patients a bilateral anterior thoracotomy
without sternal division. In 21 patients the new lungs had to
be reduced in volume to accommodate them into the
recipient’s chest cavity. Donor to recipient size mismatch
exceeding 50% was circumvented by reducing the volume
by multiple-stapled resections on both donor lungs after
reimplantation. The transplanted lungs were trimmed with
extra-anatomic wedge resections using mechanical GIA
staplers (Ethicon, Inc., Somerville, NJ) and bovine pericar-
dium sleeves (Peri-Strip surgical tape; Biovascular, Inc., St.
Paul, MN) to buttress the suture line. The resections
involved the anterior segments of the upper lobes, anterior-
basal segments of the lower lobes, the right middle lobe
and the lingula.
2.4. Postoperative management
Patients were weaned from mechanical ventilation as
soon as possible after transplantation. Immediately after
being extubated, they started chest physiotherapy and were
encouraged to walk as soon as possible. Within 48 h after
transplantation all patients underwent flexible bronchoscopy
to assess the adequacy of the bronchial anastomosis and to
detect possible infections. The primary aims of postoper-
ative management were to prevent acute rejection, control
infection, monitor renal and liver functions and optimize
immunosuppressive therapy. When discharged from hospi-
tal, patients from distant regional centres were lodged for at
least 3 months with the parents in a guest house close by the
hospital free of charge. The Latium Regional Association
for Cystic Fibrosis covered all the expenses.
Patients underwent surveillance flexible bronchoscopy
and bronchoalveolar lavage (microbiological and cytolog-
ical studies) for lower respiratory infections at 2 weeks, 1
month, 2 months, 3 months, 6 months and 12 months
postoperatively and also when clinically indicated by
physical examination, fever, increasing oxygen require-
ments, decline in FEV1 or new chest X-ray findings.
Transbronchial biopsies during flexible bronchoscopy were
obtained only when chronic or acute reject were suspected.
Lung function was assessed by flow–volume curves and on
discharge from hospital the patient was provided with a
home spirometer. The patient was asked to do spirometry
twice a day and to contact our centre if the FEV1 dropped by
more than 10% from baseline.
2.5. Immunosuppression
We used standard triple-agent immunosuppression con-
sisting of cyclosporine (CSA) or tacrolimus (FK506) or
sirolimus, azathioprine (AZA) and prednisone. CSA was
started at the end of lung transplantation as a continuous
infusion at the dose of 2 mg/kg/day in 48 patients. Toreduce the risk of renal insufficiency, in the last 7 patients
treated CSA was started 24 h after transplantation. As soon
as the patient was extubated and tolerating enteral feeding
CSA was converted to a twice daily oral dose (10 mg/kg/
day) to reach blood levels around 300–400 ng/ml during
the first year. Thereafter blood levels of CSA were
maintained in the range 200–300 ng/ml. The 11 patients
who were intolerant to CSA and the 15 who had chronic
rejection received FK506 at the starting dose of 0.2 mg/kg/
day to keep blood levels around 10–15 ng/ml. In 8
patients who had chronic renal insufficiency CSA and
FK506 were replaced with sirolimus at the dose required to
maintain a blood level of 10–20 ng/ml. To stabilize plasma
levels, CSA and FK506 were given in association with
erythromycin twice daily at doses ranging from 400 mg to
600 mg.
Before transplantation, AZA was started at an oral dose
of 2 mg/kg; after transplantation it was given via a nasal
gastric tube at the dose of 2 mg/kg/day; and when patients
ate normally was continued orally at the same dose. If the
blood leucocyte count dropped below 5.0109 L1 the
dose was halved, and if leucocyte numbers dropped to less
than 3.0109 L1 the drug was discontinued until they
returned to acceptable levels.
Steroid treatment was begun in the postoperative period
when the lungs were reperfused. Methylprednisolone was
started at an initial dose of 125 mg intravenously in three
daily bolus for 3 days, followed by prednisone, started at 25
mg/day and tapered down to an oral dose of 0.5 mg/kg/day
(maximum dose 25 mg/day).
2.6. Infection prophylaxis
All patients received preoperative antibacterial prophy-
laxis, chosen on the last sputum culture (currently a
combination of tobramycin and ceftazidime). Antimicrobial
therapy was continued for at least 14 days and adjusted on
findings in the first bronchoalveolar lavage.
Postoperative CMV prophylaxis consisted of ganciclovir
(10 mg/kg/day) for 3 weeks from day 15. In the last 4
patients, a 3-week course with ganciclovir was started only
at first virologic detention of virus in the blood (immuno-
fluorescence or quantitative polymerase chain reaction).
As postoperative prophylaxis for HV infection patients
received acyclovir (400 mg/day for those who weighed less
than 50 kg and 800 mg/day for those who weighed more
than 50 kg).
Prophylaxis against Pneumocystis carinii infection con-
sisted of double strength trimethoprim-sulfamethoxazole
given once daily three times per week, starting 7 days after
transplantation. Patients intolerant to this medication
received aerosol pentamidine (300 mg) once a month.
Postoperative fungal infections were treated according to
the specific organism cultured in sputum. If sputum cultures
grew Aspergillus fumigatus, the patient was treated either
with oral itraconazole (400 mg/day) and aerosol amphoter-
Table 2
Surgical and medical non infective complication after lung transplantation
No. of patients
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liposomal amphotericin B for 15 days (3 mg/kg/day)
followed by a 2-week course of aerosolized amphotericin B.Surgical complications
& Stenosis/dehiscence of bronchial anastomosis 12
& Surgical wound dehiscence 8
& Phrenic nerve injiury 6
& Pneumotorax 5
& Pleural empyema 5
& Pericardial effusion 4
& Osteomyelitis of the sternum 4
& Vocal cord paralysis 1
& Mediastinitis 1
Medical non-infective complications
& Diabetes 31
& Chronic renal failure 27
& Osteoporosis 17
& Arterial hypertension 14
& CSA-related neurological complications3. Statistics
Results are presented as mean plus or minus standard
deviation (SD). Survival after lung transplantation and
actuarial freedom from bronchiolitis obliterans syndrome
were calculated according to the Kaplan-Meier method. A
nonparametric test, Kendall tau B, was used to compare
means. Chi-square was used to compare categorical
variables. p values equal to or less than 0.05 were
considered to indicate statistical significance. Statistical
analysis was performed using SPSS for Windows software
system (SPSS Inc., Chicago, IL).seizures 4
transient cerebral ischaemia 1
transient cortical bilateral blindness 14. Results
Of the 114 patients with CF evaluated for lung trans-
plantation in a 6-year period, 91 patients were included in
the waiting list. Of these 114 patients, 15 were refused for
the following reasons: disease not yet end-stage (n =9),
severe renal failure (n =2), active hepatitis C (n =1), left
cardiac failure (n =1), renal failure and psychologically
unacceptable (n =1), and colonization with pan-resistant B.
cepacia (n =1). Thirty-five patients (38.5%) died while
awaiting transplantation. Fifty-five patients (51.9%) under-
went bilateral sequential lung transplantation. One patient
with grade 4 bronchiolitis obliterans syndrome had a
second transplantation 14 months after the first operation
and 41 months later she is alive and in good general
conditions. The mean time patients spent on the waiting list
was 6.8T5.2 months (range 1 day–21 months) for those
receiving lung transplantation, and 5.4T4.5 months (range
10 days–18 months) for those dying while on the waiting
list. The mean follow-up in the 55 patients was 27.3
months (range 1–72 months).Fig. 1. FEV1 (% of predicted value) in patients with cystic fibrosis who
underwent bilateral sequential lung transplantation. Baseline values, after 1,
6, 12 and 24 months of follow-up. All data were evaluated with the Kendall
tau B. p <0.005.In 12 procedures cardiopulmonary bypass was needed to
improve intraoperative unstable hemodynamics or oxygen-
ation. Interestingly, mortality was significantly higher for
those patients who received intraoperative cardiopulmonary
bypass (v2 5.3, p <0.02). Patients remained intubated after
transplantation for a mean time of 29T8 h, range 25–45 h.
Eleven patients were extubated at the end of the operation.
Patients remained in the intensive care unit for a mean time
of 6.2T2.5 days.
After transplantation all patients achieved satisfactory
lung function (Fig. 1). Mean FEV1 increased significantly
during follow-up (from 57% of the predictive value at 1
month to 71.5% at 3 months and to 82.2% at 2 years)
( p <0.0001 by Kendall Tau B test).
Surgical and medical non-infective complication after
lung transplantation are reported in Table 2. Medical non-
infective complications were probably related to immuno-
suppressive therapy. All neurological complications were
resolved with the shift to FK506.
All patients had normal renal function before trans-
plantation. Of the patients with chronic renal failure only
one is awaiting renal transplantation for severe chronic renal
insufficiency.
All 55 patients had pre-transplantation bacterial airways
infections: 48 were colonized with Pseudomonas aerugi-
nosa, 6 with B. cepacia and 1 with Staphylococcus aureus.
Post-transplantation bacterial lower respiratory tract infec-
tions developed during the follow-up in 42 patients and all
responded to specific antibiotics. One patient had Myco-
plasma pneumoniae and one patient had Chlamydia
pneumoniae pulmonary infection, both successfully treated.
Cultures of sputum or bronchoalveolar lavage fluid from
6 patients grew P. carinii. Two of these six patients were
receiving postoperative prophylaxis with pentamidine, three
with trimethoprim-sulfamethoxazole, and one patient had no
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transplantation only days previously. Of these six patients,
three had acute interstitial pneumonia.
None of the patients had positive sputum or BAL
culture for A. fumigatus before transplantation. Six
patients were colonized with A. fumigatus during the
follow-up and all of them responded to antifungal therapy;
one patient had A. fumigatus infection of the right
bronchial anastomosis and one patient with grade 4
bronchiolitis obliterans syndrome had evidence of pulmo-
nary aspergillosis at autopsy. A third patient suffered a
severe pulmonary infection with Aspergillus niger.
Among the 45 patients that survived the early post-
operative period, in 24 cases both the recipients and the
donors were CMV positive, in 9 cases only the donors were
CMV positive, in 9 cases only the recipients were CMV
positive, and in 3 cases both donors and recipients were
negative. CMV infection occurred in 41 patients during the
follow-up. One patient had CMV pneumonia and one had
gastrointestinal CMV with duodenal ulcer. All patients were
successfully treated with ganciclovir and specific CMV
antibodies. In our series we haven’t found significant
statistical correlation between CMV infection and the
development of bronchiolitis obliterans syndrome during
follow-up (v2 1.02, p =0.6).100%
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Fig. 2. (A) Freedom from bronchiolitis obliterans syndrome (grade 1 or
higher) after lung transplantation for patients who survived the early
postoperative period. (B) Actuarial survival rates after lung transplantation
in 55 recipients. Numbers in parenthesis report patients at risk.In the first 6 months after transplantation the average rate
of acute rejection, defined as the presence of fever, 10 mm
Hg decrease in PaO2, 10% fall in FEV1 from baseline,
absence of infection and good response to methylpredniso-
lone treatment, was 1.3 episodes per patient. Bronchiolitis
obliterans syndrome defined as a FEV1 less than 20% of the
baseline post-transplantation value developed in 15 (27.3%)
patients who survived the perioperative period. Freedom
from bronchiolitis obliterans syndrome was 95.1% at 1 year,
82.5% at 2 years, 70% at 3 years, and 65% at 4 years, 5 and
6 years after lung transplantation (Fig. 2A).
Actuarial survival rates were 80% at 1 month, 70% at 3
years and 58% at 6 years (Fig. 2B). Early mortality, defined
as death within 30 days after transplantation (mean survival
time 7.5 days, range 1–30 days) was 17.8% (n =10
patients). The causes of death were primary graft failure
(n =4), multiorgan failure (n =3), B. cepacia sepsis (n =1),
myocardial infarction (n =1), and pulmonary embolism
(n =1).
Nine patients (16%) died from 9 to 43 months after lung
transplantation. Two patients died of P. carinii infection at 9
and 14 months. One patient with grade 3 bronchiolitis
obliterans syndrome disease died of A. fumigatus pulmonary
infection at 24 months; four patients died of obliterative
bronchiolitis between 22 and 44 months; one patient with
grade 1 bronchiolitis obliterans syndrome died of an
unknown cause at 24 months; and one patient with
bronchiolitis obliterans grade 3 committed suicide 9 months
after transplantation.5. Discussion
Bilateral sequential lung transplantation, the only hope
for most of our relatively young patients with end-stage
cystic fibrosis, emerged as a viable option that prolongs
survival: nearly all of the patients achieved nearly normal
lung function within 6 months after transplantation. These
results compare well with the major studies similar to ours
[6,8–10,12,14].
Our program for bilateral sequential lung transplantation
in patients with CF, set up in 1996, was among the first
made available for these patients in Italy. Our experience
gained during the 6-year period reviewed underlines the
importance of a team approach of surgeons, physicians and
pediatricians in caring for patients with CF throughout the
preoperative and postoperative course. All our patients were
followed before and after transplantation by the same
medical staff, all of whom were experienced in caring for
patients with CF and continuously exchanged information
about the patients under their care. The special organization
of the Italian health system, which covers all medical
expenses, not only gave us the opportunity to offer patients
lung transplantation without social discriminations, but also
left us free to choose the most appropriate medical
treatment.
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we used only nonmarginal organs [9]. A problem that still
limits the number of lung transplants in Italy is the
availability of transplantable donor lungs. The mean time
our patients spent on the waiting list (6.7 months) was
similar to that reported for other centers in USA [9], but
shorter than that reported by Wiebe et al. in Europe [12].
The only way of increasing organ supply to meet demand is
to conduct more efficient campaigns that will encourage
people to donate organs and to develop new techniques for
organ selection and preservation.
An important point that limits the survival of patients
with CF awaiting lung transplants is the timing of referral
for transplantation. More than 38% of the patients in our
program died while still on the waiting list. Many patients
were referred from the regional centers too late, when they
already had severe disease. In previous studies of patients
with CF awaiting lung transplantation, FEV1, PaCO2, 6-min
walking distance, gender, higher systolic pulmonary artery
pressure, breathing reserve index and lactate threshold were
independently associated with an increased risk of death
while awaiting transplantation [17–21]. Unfortunately, at
the moment no single clinical variable at the time of listing
for transplantation reliably distinguishes those who die
while awaiting transplantation from those who survive until
lung transplantation. Among the criteria we used in this
study for including a patient in the waiting list, the most
important are continuous need of supplemental oxygen with
a partial pressure of carbon dioxide greater than 50 mm Hg
and a continuous need of parenteral antibiotics. Hence
decisions on the timing of transplantation should in the
future take into account other metabolic and functional
cardiorespiratory variables.
Our patients made a rapid functional recover after
surgery and rapidly returned to a normal lifestyle. This
achievement depends mainly on the young age of the
patients with CF who underwent transplantation.
Medical complications secondary to immunosuppressive
therapy were common during the follow-up, but responded
to a change in medication. The leading medical complica-
tion in our patients was chronic renal insufficiency. One
patient who has chronic renal insufficiency is awaiting
kidney transplantation. A possible reason for the high rate of
renal complications is that antibiotic therapy for acute
respiratory infections in patients with CF lowers renal
functional reserve and this situation is worsened by post-
transplantation immunosuppressive therapy with cyclospor-
ine. Patients with CF should be carefully monitored for renal
function, and be free of significant renal impairment before
lung transplantation.
Infections are an important cause of early and late
complications and death in transplant patients [11,22,23].
Although infections were a major cause of morbidity also in
our program, only four patients died of infections: one
patient (10%) during the early postoperative period and
three patients (33.3%) during the follow-up.All our patients were chronically colonized with Gram
negative and Gram positive bacteria, six patients with B.
cepacia. Only one patient was colonized with pan-resistant B.
cepacia and she died of sepsis in the early perioperative
period. In 85.7% of the patients at least one pulmonary
bacterial exacerbation developed during the follow-up; all
these episodes responded to specific antibiotics. Conse-
quently, our centre’s strategy for the prophylaxis and treat-
ment of infection proved highly successful. As other lung
transplantation programs have reported, preoperative chronic
colonization with multidrug-resistant organisms is not a
contraindication for transplantation. Whether bacterial pul-
monary infections predispose these patients to the develop-
ment of chronic pulmonary rejection remains unclear.
Another major problem our centre has to address is the
unacceptable number of opportunistic infections with P.
carinii, CMV and A. fumigatus. Sputum cultures from six
patients grew P. carinii; three of these six patients had acute
interstitial pneumonia and two died. In one patient P. carinii
infection led to the development of bronchiolitis obliterans
syndrome. Hence P. carinii is still one of the most important
infective problems in our patients. It should always be
considered in the differential diagnosis for episodes of acute
dyspnea and demands prompt specific therapy.
The role of CMV infection in the development of
bronchiolitis obliterans syndrome is controversial [24,25].
More than 70% of the patients had at least one CMV
infection, but none of our patient died. In our experience we
found no association between CMV infection and subse-
quent development of bronchiolitis obliterans syndrome.
By adulthood an estimated 50% of patients with CF will
have A. fumigatus routinely isolated from culture of sputum
or BAL [26]. Although none of our patients had positive
sputum or BAL culture for Aspergillus when they under-
went transplantation, this microorganism was isolated from
sputum or BAL from 12 patients during the follow-up. In
three of these patients it was associated with severe
pulmonary infection. In one patient A. fumigatus was not
isolated when he was alive, but was discovered only at the
post-mortem examination. Our experience underlines the
need for strict surveillance and treatment of aspergillus
infection in all transplanted patients during follow-up. Most
important, patients with cystic fibrosis may continue to
have chronic colonization of the sinus with Aspergillus,
despite negative sputum or BAL cultures.
The primary outcome variable is the actuarial survival
rates for our patients which matched those reported in other
lung transplantation programs for patients with CF [6–10].
In our series, 18% of the patients died within 30 days from
transplantation. Only 16.3% of the patients died from 9 to
43 months after transplantation. Perioperative mortality in
our program was lower than that reported by Meyers et al.
[9], but much higher than that reported by Yacoub et al. [6],
Mendeloff et al. [7], and Wiebe et al. [12]. The most
important causes of death in the early postoperative period
were primary graft failure and multiorgan failure whereas
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insufficiency and cardiac failure secondary to bronchiolitis
obliterans syndrome (44%) and pulmonary infections with
opportunistic agents (33%). Our findings provide clear
evidence that intraoperative cardiopulmonary bypass is a
negative prognostic factor for early and long term survival.
In our series, two patients died for nonmedical reasons, one
died of unknown causes and the other committed suicide.
This death draws attention to the need for specialist
assistance with psychological problems especially in young
lung transplant recipients whose postoperative course is
complicated by severe medical problems.
The major limitation to long-term survival after lung
transplantation is chronic rejection, represented by bron-
chiolitis obliterans, a syndrome whose precise cause
remains a conundrum [25–27]. Because transbronchial
biopsy sampling is an intensive diagnostic test for this
patchy histologic process, our center has used bronchiolitis
obliterans syndrome as a predominantly clinical marker of
chronic rejection. During the 72-month follow-up 15
(33.3%) of the 45 patients manifested clinical evidence of
chronic rejection. Freedom from obliterative bronchiolitis
(95% at 1 year, 82.5% at 24 months, 70.3% at 36 months
and 65% at 4, 5 and 6 years) was similar to that reported in
other case series (9, 10,12, 22). The most interesting finding
in our review was that freedom from obliterative bronchio-
litis syndrome decreased to 65% at 48 months and remained
unchanged at 60 and 72 months. Hence the risk of
obliterative bronchiolitis syndrome developing is highest
between 12 and 36 months after transplantation and there-
after is almost nil. Because of the small number of patients
in our study it is impossible to make a reasonable
association between infection, acute rejection and the
development of obliterative bronchiolitis.
In conclusion, lung transplantation again emerges as a
viable option for end-stage pulmonary disease in patients
with CF. Patients with CF are excellent candidates for lung
transplantation because they are usually still young enough
to recover rapidly after transplantation. Although bilateral
sequential lung transplantation offers an excellent quality of
life in the medium term, the major obstacle to long-term
survival are bronchiolitis obliterans syndrome and oppor-
tunistic infections. The current role of lung transplantation
in cystic fibrosis is to prolong survival in patients with end-
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